Enhancement of tumor radio-response by irinotecan in human lung tumor xenografts

Japanese Journal of Cancer Research

Volumn 88, Issue 2, 1997, Pages 218-223

  Tamura, Kenji ^a,e,f   Takada, Minoru ^a,b   Kawase, Ichirou ^a   Tada, Takuhito ^a   Kudoh, Shinzoh ^c   Okishio, Kyouichi ^c   Fukuoka, Masahiro ^d   Yamaoka, Naoki ^e   Fujiwara, Yasuhiro ^e   Yamakido, Michio ^e  

^a OSAKA PREFECTURAL MEDICAL CENTER FOR RESPIRATORY AND ALLERGIC DISEASES   (Japan)

^b Izumisano Municipal Hospital   (Japan)

^c OSAKA CITY UNIVERSITY HOSPITAL   (Japan)

^d KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e HIROSHIMA UNIV SCHOOL OF MEDICINE   (Japan)

^f NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

Author keywords

CPT 11; Lung cancer; Radiosensitization; Xenograft

Indexed keywords

DRUG METABOLITE; IRINOTECAN; RADIOSENSITIZING AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER RADIOTHERAPY; CELL CYCLE G2 PHASE; CONTROLLED STUDY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; INTRAPERITONEAL DRUG ADMINISTRATION; LARGE CELL CARCINOMA; LUNG CANCER; LUNG SMALL CELL CANCER; MALE; METAPHASE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIATION DOSE; RADIOSENSITIZATION; TUMOR REGRESSION; TUMOR XENOGRAFT;

EID: 0030892634     PISSN: 09105050     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1349-7006.1997.tb00369.x     Document Type: Article

References (31)

1. Slichenmyer, W. J Rowinsky, E. K Donehower, R. C. and Kaufmann, S. H. The current status of camptothecin analogues as antitumor agents. J. Natl. Cancer Inst 85, 271-291 (1993).
2. Potmesil, M. Camptothecins: from bench research to hospital wards. Cancer Res 54, 1431-1439 1994).
3. Schaake-Koning, C van den Bogaert, W., Dalesio, O Festen, J Hoogenhout, J. and van Houtte, P. Effects of concomitant cisplatin and radiotherapy on inoperable nonsmall-cell lung cancer. N. Engl. J. Med 326, 524-530 (1992).
4. Takada, M Fukuoka, M., Furuse, K Ariyoshi, Y Ikegani, H. and Kurita, Y. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with small cell lung cancer. 32nd Proc. Am. Soc. Clin. Oncol 372 (1996).
5. Kudoh, S Takada, M., Masuda, N Nakagawa, K Itoh, K Kusunoki, Y Negoro, S Matsui, K Takifuji, N Morino, H. and Fukuoka, M. Enhanced antitumor efficacy of a combination of CPT-11, a new derivative of camptothecin, and cisplatin against human lung tumor xenografts. Jpn. J. Cancer Res 84, 203-207 (1993).
6. Goldin, A Venditti, J. M Macdonald, J. S Muggia, F. M Henney, J. E. and Devita, V. Jr. Current results of the screening program at the Division of Cancer Treatment, National Cancer Institute. Eur. J. Cancer, 17, 129- 142 (1981).
7. Marie-Christine, B Daniel, G., Françoise, G.-V. and Françious, L. Experimental antitumor activity of Taxotere (RP56976, NSC628503), a taxol analogue. Cancer Res 51, 4845-4852 1991).
8. Thomas, H. C Wilbur, R. L Donald, J. D Billy, J. R Daniel, P. G. Jr. and Schabel, F. M Jr. Toxicity and anticancer activity of a new triazine antifolate (NSC 127755). Cancer Res 42, 1707-1715 1982).
9. Nissen, V. C. A detergent-trypsin method for the preparation of nuclei for flow cytometric DNA analysis. Cytometry, 3, 323-327 (1983).
10. Belli, J. A. and Piro, A. J. The interaction between radiation and adriamycin damage in mammalian cells. Cancer Res 37, 1624-1630 1977).
11. Phillips, T. L. and Fu, K. K. The interaction of drug and radiation effects on normal tissues. Int. J. Radiat. Oncol. Biol. Phys 4, 59-64 1978).
12. Yokes, E. E. and Weichselbaum, R. R. Concomitant chemoradiotherapy: rationale and clinical experience in patients with solid tumors. J. Clin. Oncol, 8, 911-934 (1990).
13. Choy, H Rodriguez, F. F Koester, S Hilsenbeck, S. and Vonhoff, D. D. Investigation of taxol as a potential radiation sensitizer. Cancer, 71, 3774-3778 1993).
14. Liebmann, J Cook, J. A Fisher, J Teague, D. and Mitchell, J. B. In vitro studies of taxol as a radiation sensitizer in human tumor cells. J. Natl. Cancer Inst 86, 441-446 (1994).
15. Musk, S. R. and Steel, G. G. The inhibition of cellular recovery in human tumour cells by inhibitors of topoisomerase. Br. J. Cancer, 62, 364-367 (1990).
16. Boothman, D. A Wang, M., Schea, R. A Burrows, H. L Strickfaden, S. and Owens, J. K. Posttreatment exposure to camptothecin enhances the lethal effects of x-rays on radioresistant human malignant melanoma cells. Int. J. Radiat. Oncol. Biol. Phys 24, 939-948 (1992).
17. Boscia, R. E Korbut, T., Holden, S. A Ara, G. and Teicher, B. A. Interaction of topoisomerase I inhibitors with radiation in cw-diammine dichloroplatinum (II)sensitive and -resistant cells in vitro and in the FSAIIC fibrosarcoma in vivo. Int. J. Cancer, 53, 118-123 (1993).
18. Mattern, M. R Hofmann, G. A McCabe, F. L. and Johnson, R. K. Synergistic cell killing by ionizing radiation and topoisomerase I inhibitor topotecan (SK&F 104864). Cancer Res 51, 5813-5816 1991).
19. Kim, J. H Kim, S. H Kolozsvary, A. and Khil, M. S. Potentiation of radiation response in human carcinoma cells in vitro and murine fibrosarcoma in vivo by topotecan, an inhibitor of DNA topoisomerase I. Int. J. Radiat. Oncol. Biol. Phys 22, 515-518 (1992).
20. Terashima, R. and Tolmach, L. J. X-ray sensitivity and DNA synthesis in synchronous populations of Hela cells. Science, 140, 490-492 (1963).
21. Sinclair, W. K. and Morton, R. A. X-ray sensitivity during the cell generation cycle of cultured Chinese hamster cells. Radiat. Res 29, 450-474 1966).
22. Hall, E. J. "Radiobiology for the Radiologist," Ed. 3 1988). J. B. Lippincott, Philadelphia.
23. Falk, S. J. and Smith, P. J. DNA damaging and cell cycle effects of the topoisomerase I poison camptothecin in irradiated human cells. Int. J. Radiat. Biol 61, 749-757 1992).
24. Strome, G Distelmans, W., De Neve, W. Interaction between microtuble inhibitors and ionizing radiation. In "Antitumor Drug-Radiation Interaction," ed. B. T. Hill and A. S. Bellamy, pp. 107-124 1990). CRC Press, Boca Raton, Florida.
25. Tishler, R. B Gerard, C. R Hall, E. J. and Schiff, P. B. Taxol sensitized human astrocytoma cells to radiation. Cancer Res 52, 3495-3497 1992).
26. Li, L. H Fraser, T. J Olin, E. J. and Bhuyan, B. K. Action of camptothecin on mammalian cells in culture. Cancer Res 32, 2643-2650 1972).
27. Horwitz, S. B. and Horwitz, M. S. Effects of camptothecin on the breakage and repair of DNA during the cell cycle. Cancer Res 33, 2834-2836 1973).
28. Drewinko, B Freireich, E. and Gottlieb, J. Lethal activity of camptothecin sodium on human lymphoma cells. Cancer Res 34, 747-750 (1974).
29. D'Arpa, P Beardmore, C. and Liu, L. F. Involvement of nucleic acid synthesis in cell killing mechanisms of topoisomerase poisons. Cancer Res 50, 6919-6924 1990).
30. Kastan, M. B Onyekwere, O., Sidransky, D Vogelstein, B. and Craig, R. W. Participation of p53 protein in the cellular response to DNA damage. Cancer Res 51, 6304- 6311 1991).
31. Del Bino, G Bruno, S., Yi, P. N. and Darzynkiewicz, Z. Apoptotic cell death triggered by camptothecin or teniposide. The cell cycle specificity and effects of ionizing radiation. Cell Prolif, 25, 537-548 (1992).